BMC Medical Co. Ltd. raised ¥1.918 billion (US$264 million) on the Shenzhen Stock Exchange. Its shares opened on Nov. 1 at ¥230 per share, surged more than 140% in the middle of the day and closed at ¥290.
Human Immunology Biosciences (HI-Bio) Inc., a company developing targeted therapies for severe immune-mediated diseases, has secured $120 million in financing. Its initial pipeline is built around two clinical-stage immunology assets in-licensed from Morphosys AG in June 2022. The funds will help the company move through key inflection points over the coming years, in both in its ongoing clinical and discovery programs, where it's currently focused on the role of mast cells as a cellular driver of disease.
Think Surgical Inc. has just received a $100 million investment from a new investor, South Korea’s KDB Investment Global Healthcare, a private equity firm that is wholly owned by Korea Development Bank. The Fremont, Calif.-based orthopedic surgical robotic company will use the funds to bring new products to market. Stuart Simpson, president and CEO of Think Surgical, confirmed that it will go towards supporting “successful new product commercialization.”
Ariemedi Medical Technology (Beijing) Co. Ltd. has completed a series A+ round to further develop its medical devices for minimally invasive surgeries. The round was co-invested by Haining Hairui Investment Management Co. Ltd. and Haier Capital.
RSS
